New FDA action reshapes paediatric fluoride policy in the US

SILVER SPRING, Md., US: The US Food and Drug Administration (FDA) has announced new enforcement actions to restrict the sale of ingestible fluoride drug products for children. This step is intended to direct manufacturers to stop marketing products labelled for use in children under 3 years and in older children who are not at high risk of dental caries. The decision follows a formal scientific evaluation of fluoride supplements used in the paediatric population and months of public consultation. It marks a significant shift in federal oversight of products that have been prescribed for decade